- Home
- DVAX
as 01-17-2025 4:00pm EST
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 1.7B | IPO Year: | 2004 |
| Target Price: | $23.00 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.15 | EPS Growth: | -67.55 |
| 52 Week Low/High: | $9.74 - $14.30 | Next Earning Date: | 02-20-2025 |
| Revenue: | $260,810,000 | Revenue Growth: | -27.79% |
| Revenue Growth (this year): | 21.64% | Revenue Growth (next year): | 19.81% |
Latest Dynavax Technologies Corporation News
DVAX Breaking Stock News: Dive into DVAX Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Dynavax Technologies (DVAX) Upgraded to Buy: Here's What You Should Know
Argus Research
4 days ago
DVAX: What does Argus have to say about DVAX?
TipRanks
5 days ago
Dynavax Reports Revenue Growth and Defense Contract
PR Newswire
6 days ago
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
Zacks
16 days ago
Implied Volatility Surging for Dynavax Technologies (DVAX) Stock Options
Argus Research
a month ago
DVAX: What does Argus have to say about DVAX?
Argus Research
a month ago
DVAX: What does Argus have to say about DVAX?
Argus Research
a month ago
DVAX: What does Argus have to say about DVAX?
Compare DVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DVAX Dynavax Technologies Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.